Law360, New York (December 22, 2011, 7:56 PM ET) -- European and Canadian heath regulators are investigating a Novartis AG diabetes drug and advising doctors to stop prescribing it in combination with two other types of drugs for the time being, the regulators announced Thursday.
The European Medicines Agency and Health Canada said they are investigating all diabetes drug brands containing aliskiren after pharmaceutical giant Novartis' Tuesday announcement that it was halting a study involving the drug because of potential dangers.
Aliskiren was approved in 2007 in the EU and U.S. under the brand names Rasilez...
Canada, EU To Probe Novartis Diabetes Drug
To view the full article, take a free trial now.
